Perrigo closes two plants
This article was originally published in The Tan Sheet
Executive SummaryThe private labeler is closing its Holland and Montague, Mich.-based manufacturing facilities and will "transfer its profitable product lines" from those locations to plants based in Allegan, Mich. and The Bronx, N.Y., Perrigo announces June 27. The firm will discontinue production for its unsuccessful psyllium-based laxatives and effervescent tablets. The closings correspond with Perrigo's business strategy to improve efficiency and successfully integrate Agis, an Israeli generics firm acquired in March 2005, the firm states. Perrigo estimates an $8 mil. pre-tax charge will be incurred during Q4 2006 (ending July 1) as well as a $3 mil. one-time cost during fiscal 2007 as a result of the plant closings. All 140 employees affected by the closing plants will be offered positions at the Allegan site, Perrigo says...
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.